Oppenheimer Maintains Outperform on Pelthos Therapeutics, Lowers Price Target to $64

Benzinga Newsdesk www.benzinga.com Negative 93.3%

Neg 93.3% Neu 0% Pos 0%

Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and lowers the price target from $66 to $64.